Skip to main content
. 2014 Jul 21;6:79–89. doi: 10.2147/RRU.S43125

Table 1.

Outcomes of placebo-controlled trials

Study (time point of reporting) Dose (N) Urgency incontinence episodes Urgency Symptom scores Patient-reported measures
Chapple et al26 (week 12) Change in IE/day Change in urgency/day Positive response on TBS
 100 U (277) −2.95 (P<0.001) −2.95 (P<0.001) 62.8% (P<0.001)
 Placebo (271) −1.03 −1.24 26.8%
Nitti et al27 (week 12) Change in IE/day Change in urgency/day Positive response on TBS
 100 U (280) −2.65 (P<0.001) −2.93 (P<0.001) 60.8% (P<0.001)
 Placebo (277) −0.87 −1.21 29.2%
Denys et al24 (month 3) >75% reduction in symptoms
 50 U (21) 6%
 100 U (22) 42% (P=0.03)
 150 U (27) 42% (P=0.03)
 Placebo (29) 22%
Dmochowski et al23 (week 12) Proportion IE free
 50 U (57) 29.8%
 100 U (54) 37.0%
 150 U (49) 40.8%
 200 U (53) 50.9%
 300 U (56) 57.1%
 Placebo (44) 15.9%
Tincello et al25 (month 6) IE/day Urgency/day Urgency severity score IQOL
 200 U (122) 1.67 (P=0.0001) 3.83 (P<0.0001) 1.50 (P=0.0006) 55.11 (P<0.0001)
 Placebo (118) 6.0 6.33 1.9 27.27
Brubaker et al22 (day 60 [clinical hold]) 75% reduction UDI-urge subscale PGI-I score
 200 U (28) 72%* 31 (P=0.003) 2.7 (P=0.003)
 Placebo (15) 0% 52 4.0
Sahai et al20 (week 12) Change in IE/day Difference in UDI-6 Difference in IIQ-7
 200 U (16) −3.50 (P<0.0076) −5.13 (P<0.0001) −10.38 (P=0.0063)
 Placebo (18) −0.71 +0.5 +0.61
Flynn19 (week 6) Change in IE/day Difference in UDI Difference in IIQ
 200 U or 300 U (15) −4.5 (P<0.01) −18.6 (P=0.04) −39.5 (P=0.02)
 Placebo (7) +0.7 +3.1 0

Note:

*

P-value<0.0001.

Abbreviations: IE, incontinence episodes; IIQ, Incontinence Impact Questionnaire; IQOL, incontinence quality of life; PGI, Patient global impression of improvement; TBS, Treatment Benefit scale; UDI, Urinary Distress Inventory scale.